Early intervention improves the likelihood of repigmentation, and can reduce disease progression…

Vitiligo is an autoimmune disorder in which melanocytes are selectively destroyed by the immune system, resulting in depigmented skin patches. Approximately half of cases develop before 20 years of age.

The condition has a relapsing and remitting course. Disease activity varies over time, and there are no validated biomarkers to measure activity. Clinicians must therefore rely on serial clinical assessment and photography to determine whether lesions are progressing or stabilising.

Vitiligo is increasingly relevant in Australian primary care as the population becomes more ethnically diverse. Although it affects all skin types and ethnicities, the cosmetic contrast is often more pronounced in people with darker skin tones.

The psychosocial burden is substantial

While vitiligo itself is medically benign, the psychosocial consequences can be profound. Patients can experience embarrassment, stigma, social isolation, anxiety, low self-esteem, and impaired quality of life. Cultural factors can intensify the burden. In some communities, vitiligo remains heavily stigmatised, affecting social relationships and even marriage prospects. Children and adolescents can be particularly vulnerable, making timely intervention important for younger patients.

Recognising vitiligo in general practice

Vitiligo usually presents as sharply demarcated depigmented white macules or patches without any scale. The borders are typically well defined. Some patients develop a “confetti” or mottled appearance, which can indicate active disease.

Vitiligo can affect almost any anatomical site, including the face, eyelids and lips, axillae and torso, arms and legs, hands and feet, genitals, and scalp.

Clinical clues favouring vitiligo

Features that support a diagnosis of vitiligo include:

• Complete depigmentation rather than mild hypopigmentation
• Absence of scale
• Symmetrical distribution
• Involvement of peri-orificial sites, hands, or genital skin
• White hair within lesions (leucotrichia)
• Progressive enlargement over time

Differential diagnoses

Several common conditions can mimic vitiligo.

Pityriasis alba

Common in children. Lesions are hypopigmented, rather than completely depigmented, and can have a fine scale.

Pityriasis versicolor

Typically affects the trunk in adolescents or young adults. A fine scale can become apparent with scratching of the lesion.

Idiopathic guttate hypomelanosis

Small white macules associated with chronic sun damage on the arms and legs, usually stable in size.

Congenital lesions

Conditions such as hypochromic naevi, albinism and piebaldism are present from birth, and tend to remain stable over time.

Practice tip: Vitiligo is usually scale-free. If a “white patch” has appreciable scale, consider alternative diagnoses such as pityriasis versicolor, eczema, psoriasis, or tinea.

Triggers and disease activity

Vitiligo can be triggered or exacerbated by both psychological and physical stress. The Koebner phenomenon is a well-recognised indicator of active disease. It refers to the development of new lesions at sites of friction, pressure or trauma. Common triggers include tight belts, tight shoes, and repetitive rubbing of the skin. Patients should be advised to minimise skin trauma where possible.

As disease activity can fluctuate over time, obtaining a careful history is important to enable assessment of the urgency of treatment and the likelihood of response.

Ask whether:

• New lesions are appearing
• Existing lesions are enlarging
• The condition is progressing rapidly
• Hair within lesions remains pigmented

If patients respond “yes” to these questions, treatment should be initiated promptly, and referral to a dermatologist considered, especially if extensive or rapidly evolving vitiligo is suspected. Retained pigment within hairs is a favourable prognostic sign, suggesting a greater likelihood of repigmentation with treatment. For patients who respond “no”, the disease may be relatively stable. While these cases can still respond to treatment, complete repigmentation becomes less likely as the extent of involvement and duration of disease increase.

Prognostic factors: location matters

One of the most clinically useful concepts for GPs is understanding that prognosis depends on hair follicle density. Melanocyte reservoirs persist within hair follicles. If pigmented hairs remain within lesions, there is greater potential for repigmentation, because melanocytes can migrate back into the epidermis.

There are more hair follicles per square centimetre on the face than any other body part, so the prognosis is better than parts of the body with less dense coverage.

Better prognosis

• Face
• Hair-bearing trunk

Intermediate prognosis

• Limbs and torso

Poor prognosis

• Fingers
• Knuckles
• Periungual skin
• Hands and feet
• Mucosal surfaces

Early disease responds better than longstanding disease.

Practice tip: Look closely at the hairs. Black hairs within vitiligo patches are a favourable prognostic sign, and suggest repigmentation can be achieved with treatment.

Treatment

Management of vitiligo has two aims: to stop the autoimmune attack and to repopulate the skin with melanocytes. When counselling patients, it is important to clarify that topical therapies primarily suppress inflammation and halt progression. They may not fully repigment skin, unless combined with phototherapy.

First-line treatment in general practice

Treatment selection depends on disease extent, anatomical site, and disease activity. For localised vitiligo treatment can be initiated in general practice with topical corticosteroids or tacrolimus, before arranging phototherapy. Patients with extensive or progressive disease require early referral for phototherapy, which is used concurrently with topical therapy.

Topical therapy

Body lesions

A mid-potency 15-gram-sized topical corticosteroid is generally recommended for body lesions. Daily application is advised for at least one month, rather than the short courses commonly used for eczema.

Facial lesions

Tacrolimus 0.1% ointment or cream is preferred for facial involvement. This avoids steroid-induced side-effects such as rosacea or skin atrophy.

Janus kinase (JAK) inhibitors

Topical ruxolitinib can be useful for patients with active or progressive vitiligo, particularly on the face and when conventional topical therapies are ineffective. The cost of ruxolitinib is a limiting factor in Australia, as it is not PBS subsidised.

Phototherapy: the cornerstone of treatment

Phototherapy serves both the therapeutic goals of immune suppression and repigmentation through melanocyte stimulation.

Narrowband ultraviolet B (UVB)

Supervised narrowband UVB phototherapy is typically administered in a dermatology clinic, with patients attending two or three times weekly and receiving treatment in a full-body phototherapy cabinet.

Handheld UVB devices

Handheld devices offer a practical option for localised disease. A TGA-approved handheld UVB device is available for purchase online, and can be safely used at home under medical guidance.

Excimer lamp therapy

Excimer devices deliver higher-intensity targeted UV therapy that can achieve repigmentation with fewer treatments, while minimising exposure and tanning of the surrounding skin.

Heliotherapy

Natural sunlight can also be used therapeutically under dermatologist supervision. However, as with treatment in a full-body UVB cabinet, excessive tanning of unaffected skin may increase the contrast between affected and unaffected skin, making vitiligo more noticeable.

Practice tip: Set realistic expectations early. Improvement can take months, and optimal outcomes may require prolonged treatment over a few years. Serial photographs every three months can help patients appreciate gradual progress.

Camouflage therapies

Cosmetic camouflage can substantially improve quality of life. Zanderm™ contains the same ingredient used in self-tanning products but in a pen applicator, providing temporary colour matching of depigmented areas without interfering with UV therapy. Camouflage products may be especially useful for facial lesions, social events, adolescents and young adults, or patients awaiting specialist review.

Surgery and depigmentation therapy

Surgical approaches such as cellular grafting can benefit selected patients with stable disease. However, these procedures are specialised and generally reserved for refractory cases. For extensive disease where repigmentation is not possible, depigmentation of remaining normal skin using monobenzyl ether of hydroquinone can be considered. These therapies require specialist management.

Counselling patients about treatment outcomes and duratio

Vitiligo treatment requires patience and persistence. A patient receiving UVB therapy two to three times weekly may achieve maximal repigmentation only after several years of treatment. Patients should understand:

• Treatment response is site-dependent: hands and feet respond poorly
• The appearance of vitiligo may be accentuated during treatment with full body UVB phototherapy due to tanning of the surrounding skin
• Full repigmentation may not be possible, especially in poor prognostic areas

The endpoint of treatment is reached when maximal repigmentation has been achieved and no new lesions are developing.

Managing active or rapidly progressive disease

Patients with rapidly progressive vitiligo may require systemic therapy. Options include oral mini-pulse dexamethasone, methotrexate or oral JAK inhibitors.

A commonly used regimen is dexamethasone 4 mg twice weekly on weekends for three months. These patients should generally be referred to a dermatologist.

Stable disease and relapse management

Stable disease refers to lesions that remain unchanged in size after treatment has been discontinued, following completion of the maximum appropriate treatment course. At this stage, patients should be counselled regarding:

• Avoiding excessive sun exposure to minimize contrast between affected and unaffected skin caused by tanning
• Use of camouflage products, where appropriate
• Monitoring for signs of relapse
• Restart treatment promptly if recurrence occurs

Vitiligo commonly relapses, often affecting the same anatomical sites that were previously involved.

Practice tip: If vitiligo is suspected, commence appropriate topical therapy promptly, while arranging dermatology review. Early treatment improves the chance of repigmentation.

When to refer

Referral to a dermatologist is appropriate in most cases, especially when patients have:

• Recent onset
• Extensive involvement
• Rapidly progressive disease
• Diagnostic uncertainty
• Poor response to initial therapy
• Significant psychosocial distress

Referral should not delay treatment initiation. A major concern is that patients are sometimes told vitiligo is “untreatable”, resulting in lost time and poorer outcomes.

Key clinical takeaways

• Vitiligo is a treatable autoimmune condition
• Early treatment improves the likelihood of repigmentation, so initiate topical therapy while awaiting specialist review
• Facial lesions have a better prognosis than hands or feet
• Pigmented hairs within lesions predict a better treatment response
• New or enlarging lesions, rapid spread, or lesions at trauma sites signal active disease warranting prompt treatment escalation and referral
• Set realistic expectations around treatment timelines and outcomes